Search Results - paul+erhardt

7 Results

Sort By:

Confederated C Prime Agents vs Cancers (PDAC) & Metabolic Disorders

Project ID: D2020-28 Background Based upon the success of a mixture of simvastatin (SIM) + metformin (Met) + digoxin (Dig), dubbed “C3”, for treating pancreatic ductal adenocarcinoma (PDAC) via a pleiotropic mechanism where attenuation of the BIRC5 pathway is a major component, we have pursued novel, single-molecular constructs that combine...

Published: 6/4/2025 | Inventor(s): Paul Erhardt, Shi-He Liu, F. Charles Brunicardi, Divya Andy

Keywords(s):

Category(s): Oncology

Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same

Novel PPARδ Agonists for Bone Growth Background Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone loss. There are...

Published: 9/25/2025 | Inventor(s): Bruce Heck, Paul Erhardt, Brian Kress, DongHyun Kim

Keywords(s):

Category(s): Long Bone/Joint Repair, Oncology

Advancement in Platinum Based Cancer Therapeutics

Project ID: D2013-02 Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer...

Published: 1/2/2025 | Inventor(s): Stephan Patrick, Paul Erhardt

Keywords(s): Cisplatin, Clinical Trials, DNA Repair, Ovarian Cancer, Platinum

Category(s): Oncology

Compounds for non-lethal micropinocytosis and exosome production

Project ID: D2017-25 Background Exosomes are vesicles in the range of 30 to 120nm, which are released from mammalian cells when multi-vesicular endosomes fuse with the plasma membrane. In recent times, exosomes have been implicated in cancer. Mounting evidence suggests that exosomes play an important role in mediating intercellular communication...

Published: 10/2/2025 | Inventor(s): William Maltese, Paul Erhardt, Zehui (Lesley) Li, Christopher Trabbic

Keywords(s): Cancer, Exosome, Vacuole, Vesicle

Category(s): Neuroscience, Oncology, Diagnostics

Compounds for disrupting microtubule networks and mitosis in brain cancer

Project ID: D2014-42 Background Primary brain tumors and secondary intracranial tumors from metastatic spread of other cancers (e.g., melanoma, lung carcinoma) have been inaccessible to therapy with microtubule-targeted agents (vincristine, vinblastine, paclitaxel) because the latter do not readily cross the blood-brain barrier. Invention...

Published: 6/18/2024 | Inventor(s): William Maltese, Paul Erhardt, Christopher Trabbic, Jean Overmeyer

Keywords(s):

Category(s): Neuroscience, Oncology

Cancer Therapy via Simultaneous Non-apoptotic Cell Death Mechanisms

Project ID: D2018-15 Background Most of current cancer therapy employs drugs that act through apoptotic signaling pathways. However, cancer cells often acquire mutations that can diminish apoptosis and lead to chemo-resistance when coupled with increased capacity for drug efflux and DNA repair. This results in chemotherapeutic failure especially...

Published: 6/18/2024 | Inventor(s): Amit Tiwari, Chandrabose Karthikeyan, Haneen Amawi, Paul Erhardt, Piyush Trivedi

Keywords(s): Autophagy, Cancer, Drug-resistance, Methuosis, Non-apoptotic cell death

Category(s): Oncology

Advancement in Platinum Based Cancer Therapeutics

Project ID: D2014-33Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells....

Published: 6/18/2024 | Inventor(s): Paul Erhardt, Stephan Patrick, Christopher Trabbic

Keywords(s): Cisplatin, Clinical Trials, DNA Repair, Ovarian Cancer, Platinum

Category(s): Oncology, Tools